Trust, emotions and risks: Pregnant women's perceptions, confidence and decision-making practices around maternal vaccination in France. by Karafillakis, E et al.
Vaccine 39 (2021) 4117–4125Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineTrust, emotions and risks: Pregnant women’s perceptions, confidence
and decision-making practices around maternal vaccination in Francehttps://doi.org/10.1016/j.vaccine.2021.05.096
0264-410X/ 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: emilie.karafillakis@lshtm.ac.uk (E. Karafillakis).E. Karafillakis ⇑, M.R. Francis, P. Paterson, H.J. Larson
Vaccine Confidence Project, Department of Infectious Diseases Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Topical Medicine, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 14 January 2021
Received in revised form 25 May 2021
Accepted 28 May 2021
Available online 4 June 2021
Keywords:
Maternal vaccination
Vaccine confidence
Trust
Decision-making
Emotions
Risk perception
FranceMaternal vaccination is an important strategy to reduce maternal and newborn mortality and morbidity.
Yet, vaccination uptake is suboptimal in many countries, including France. This mixed-method study
aimed to identify factors influencing maternal vaccination, exploring pregnant women’s perceptions,
confidence, and decision-making processes in France. Maternal vaccination uptake was positively associ-
ated with awareness of maternal vaccines, confidence in vaccine effectiveness and receiving a recom-
mendation from a healthcare professional. A trusting relationship with healthcare professionals was
observed as crucial for women during pregnancy. Even if women considered themselves as sole
decision-makers, healthcare professionals’ role in decision-making was viewed as substantial.
Pregnancy can be a complex time for assessing risks, which was evident in the strong emotional reactions
to maternal vaccination and anxieties about safety. As new maternal vaccines are developed, it is crucial
to consider women’s values, risk perceptions and emotions in the development of strategies to support
acceptance of maternal vaccination.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Maternal vaccination has become an increasingly important
component of global strategies to reduce maternal and newborn
mortality and morbidity [1]. Recommendations vary by country,
in part due to differences in disease burden, but commonly include
vaccination against influenza, tetanus and pertussis [2].
Since 2012, the inactivated influenza vaccine is officially recom-
mended for pregnant women in France, while tetanus vaccination
is only given to women considered at high-risk of infection and
pertussis vaccination is given before or after pregnancy as part of
a cocooning strategy [3]. The benefits of vaccinating pregnant
women against influenza are two-fold; preventing influenza com-
plications for the mother, and providing indirect protection to
newborns, who are at higher risk of severe and sometimes fatal
infection [4,5].
Despite official recommendations to vaccinate pregnant women
against influenza, coverage for influenza vaccination among preg-
nant women in France was estimated at around 7% in 2016 [6,7].
This reflects a decrease in influenza vaccination coverage among
all high-risk groups in France, in part explained by the spread of
controversies since the 2009 AH1N1 pandemic [6]. Other factorshave been proposed to explain this decreasing trend, including
low awareness of influenza vaccination among pregnant women,
insufficient promotional campaigns and recommendations by
healthcare professionals (HCPs), as well as concerns about vaccine
side effects [6,8]. These results also reflect the overall and historical
context of mistrust and low confidence in vaccination in the coun-
try. France was identified as the country with the lowest confi-
dence in the safety and effectiveness of vaccines globally in a
2016 study [9]. The effects of this generalised vaccine mistrust
on pregnant women’s attitudes towards and confidence in mater-
nal vaccination are unclear.
While a growing body of research contributes to the under-
standing of factors influencing uptake of maternal vaccination
globally [10], evidence remains sparse in France. This mixed-
method study aimed to explore the perceptions, confidence levels
and decision-making practices around maternal vaccination
among pregnant women in France. Such evidence can be crucial
to inform strategies aimed at increasing current and future mater-
nal vaccine uptake within the French national immunisation
programme.2. Methods
This study is part of a larger mixed-method research project
investigating attitudes towards maternal vaccination worldwide.
E. Karafillakis, M.R. Francis, P. Paterson et al. Vaccine 39 (2021) 4117–4125We collaborated with WIN/Gallup International Association (WIN/
GIA) to recruit pregnant women and conduct surveys, interviews
and focus groups in France. WIN/GIA collaborated with their local
partner to obtain access to a panel of participants fromwhich preg-
nant and recently pregnant women were selected. All study mate-
rials were developed in English and translated into French by local
translators.
2.1. Quantitative methodology
2.1.1. Survey and data collection
A representative sample of pregnant and recently pregnant
women (last child < 2 years old) were invited to participate in
internet surveys in January 2019. These women were recruited
from a nationwide panel of participants with relevant demo-
graphic information maintained by WIN/GIA’s local partner in
France. A quota-based sampling methodology was used to ensure
that the sample of women was representative of the population
distribution in the different regions of France (Supplemental
Table 1). Most women included in the study had a recent preg-
nancy (n = 386, 77%), potentially influencing their recall of previ-
ous maternal vaccinations. The survey questionnaire included
questions on women’s attitudes towards vaccines in general (not
focusing on specific childhood, adolescent or adult vaccines) and vac-
cination during pregnancy (both collected on a 5-point Likert
scale), sources of information for maternal vaccination decisions,
previous vaccination (self-reported), future maternal vaccination
intentions, and socio-demographic characteristics.
2.1.2. Study variables
The outcomes, dichotomized as ‘‘yes” and ‘‘no” (no or don’t
know) for the analyses, were: 1) ever receiving a vaccination dur-
ing pregnancy (also called ‘‘maternal vaccination uptake”) and 2)
intention to be vaccinated in a future pregnancy. All participant
characteristics were considered as potential explanatory factors
in the analyses. Women’s attitudes towards the importance, safety,
effectiveness, and religious compatibility of vaccines during preg-
nancy were dichotomized as ‘‘agree” (strongly agree or tend to
agree) or ‘‘not agree” (strongly disagree, tend to disagree, neither
agree nor disagree or don’t know). Women’s concerns about illness
during pregnancy, awareness about maternal vaccination, and
whether they received an HCP recommendation for vaccination
during pregnancy were also dichotomized. The socio-
demographic variables investigated were age, relationship status,
pregnancy status, employment, annual household income, educa-
tional attainment, and religious affiliation. The missing data (‘‘pre-
fer not to say”) percentage was low for marital status (1%),
educational attainment (1%), employment status (1%) and house-
hold income (3%). Since the missing data percentage for religious
affiliation was higher (14%), the ‘‘prefer not to say” responses were
added as a separate category in the analyses.
2.1.3. Statistical analysis
Descriptive analyses were performed using means, standard
deviations, and proportions for the study variables. Univariate
analyses were conducted to assess the strength of association
between the outcomes and each of the participant characteristics
using the chi-square or Fisher’s exact test as appropriate. Charac-
teristics with an uncorrected p < 0.25 in the univariate analyses
were included in the multivariate models using previously
described methods [11]. Multivariate logistic regression was used
to assess the participant characteristics independently associated
with maternal vaccination uptake and future vaccination inten-
tions. A backward stepwise method was used to retain variables
with an uncorrected p < 0.10 in the final multivariate models. We
used a parsimonious modelling strategy, accounting for marginally4118significant associations between the explanatory variables and
outcomes [12]. Hosmer and Lemeshow’s goodness-of-fit test was
used to evaluate the performance of the individual regression
models. Multicollinearity between independent variables in the
models was assessed using the variable inflation factor (VIF).
Results of the logistic regression models were measured using
crude and adjusted odds ratios (ORs) and presented with their
95% confidence intervals (CIs). We reported Holm-Bonferroni cor-
rected p-values for the estimates from the multivariate logistic
regression models as stepwise methods are known to inflate the
probability of Type I errors (false positive results) [13]. Holm-
Bonferroni corrected p-values below the 0.05 threshold were con-
sidered statistically significant. We also conducted sensitivity anal-
yses to assess the impact of combining the ‘‘don’t know” responses
to the ‘‘no” categories for the outcomes of interest. All analyses
were conducted in Stata 16 (StataCorp LP, College Station, TX, USA).
2.2. Qualitative methodology
2.2.1. Data collection
Semi-structured interviews and focus group discussions were
conducted with pregnant women in their first, second or third tri-
mester (<18 years old). Participants were recruited from two cities,
Paris and Toulouse, selected to include different urban environ-
ments. Participants were purposively selected to include women
with positive and negative attitudes towards maternal vaccination
by including the following screening question in the recruitment
phase: ‘‘On a scale of 1–10, could you tell me how strongly you
agree or disagree with this statement, where 10 is agree com-
pletely and 1 is disagree completely: ‘I would take any vaccine rec-
ommended to me by a doctor’”. Recruiters were asked to include a
mix of women who responded 1–3, 4–7 and 8+. Data was collected
in French in February 2019 by local experienced professionals
briefed on the objectives of the study. We aimed to conduct 20
semi-structured interviews (10 per city) and four focus groups
with eight participants each. Two focus groups were conducted
in each city: one for first time pregnancies, and a second group
of women previously pregnant.
Topic guides were designed to collect data on awareness, expe-
riences, perceptions, attitudes and decision-making factors influ-
encing vaccination in pregnancy, while encouraging participants
to share their views and opinions freely. While questions
addressed maternal vaccination in general, discussions focused
on influenza vaccination, the only vaccine officially recommended
for pregnant women in France. Participants were compensated for
travel and participation in the research.
2.2.2. Data analysis
Anonymised transcripts were translated into English and
imported into Nvivo for analysis. An initial coding framework
was developed by deductively drawing codes from the topic
guides, research objectives and analytical memos. Five transcripts
were coded using the initial coding framework, using a more
inductive process to derive additional codes from close readings
of the data. The final coding framework was reviewed and used
for the remaining transcripts and key themes were derived from
a thematic analysis.
2.3. Data management and ethical approval
Data was collected by WIN/GIA following strict industry stan-
dards laid down by the professional bodies they subscribe to, such
as the World Association for Public Opinion Research (WAPOR).
Ethical approval was received to conduct secondary data analysis
from the London School of Hygiene & Tropical Medicine (LSHTM)
Ethics Committee in May 2019 (LSHTM ethics ref: 17100).
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voluntary, and that they could withdraw from the study or refuse
to answer any questions during data collection. Verbal or written
informed consent was required to take part in the study. All partic-
ipants included in the qualitative study approved audio recording
of the discussions.
To ensure confidentiality, all data files were anonymised. Addi-
tional care was taken to remove personal identifiers from the
anonymous quotations used in this paper, with codes assigned to
participants (T for Toulouse and P for Paris). Data files were stored
on an LSHTM secure server on password-protected computers.
Data will be stored for ten years, and the records documenting
the management of the project will be stored for six years follow-
ing the completion of the research study, as per LSHTM’s Records
Retention and Disposal Schedule guidance.3. Results
3.1. Participant characteristics
A total of 500 pregnant and recently pregnant women were sur-
veyed across 13 regions in France. The majority of women were
from the Ile-de-France (n = 98, 20%), Auvergne Rhone Alpes
(n = 63, 13%) and Hauts-de-France (n = 59, 12%) regions (Supple-
mental Table 1). The mean age of women in the survey was
32 years. Over half the women had a university education or higher
(n = 307, 62%) and a similar proportion were employed during the
survey (n = 304, 62%) (Table 1). About a third of the women were
Roman Catholic (n = 174, 35%) and just under a third were Athe-
ist/Agnostic (n = 146, 29%).
The qualitative research included 53 pregnant women aged
between 24 and 41 years, 20 of which took part in interviews
and 33 in focus groups. Overall, 12 women responded 1–3 to the
screening question on their views on vaccination (classified as neg-
ative views towards vaccination); 21 women responded 4–7 (nei-
ther negative nor positive), and 19 women responded 8+
(positive views towards vaccination). Data was missing for one
woman. Focus groups included either one (P11, T11), two (P12),
or three women (T12) with negative views towards vaccination.3.2. Factors influencing maternal vaccination uptake and future
vaccination intentions
Just over a fifth of the women surveyed (n = 113, 23%) reported
ever receiving a vaccination during pregnancy and a quarter
(n = 126, 25%) intended to be vaccinated in future pregnancies. In
the univariate analyses, awareness about maternal vaccines, agree-
ing that vaccines during pregnancy are important, safe and effec-
tive, receipt of an HCP recommendation for vaccination, deciding
on vaccination for self, being currently pregnant and having a
higher household income were positively associated with both
maternal vaccination uptake and future vaccination intentions
(Table 1).
In the multivariate analyses, receipt of an HCP recommendation
for vaccination during pregnancy was one of the strongest predic-
tors of maternal vaccination uptake (Adjusted odds ratio (aOR):
11.10, 95% CI: 6.06–20.34) and women’s future vaccination inten-
tions (aOR: 3.27, 95% CI: 1.80–5.93) (Table 2). Women who agreed
that vaccines during pregnancy are effective were more likely
(than women who disagreed that vaccines during pregnancy are
effective) to have received a maternal vaccination previously
(aOR: 3.44, 95% CI: 1.96–6.05) and were more likely to be willing
to be vaccinated in a future pregnancy (aOR: 3.83, 95% CI: 2.25–
6.50). Awareness of currently available maternal vaccines was pos-
itively associated with maternal vaccination uptake (aOR: 3.65,411995% CI: 2.06–6.44) (Table 2). Women who had reported ever being
vaccinated during pregnancy were four times more likely to be
willing to be vaccinated in future pregnancies than those who
had not been vaccinated previously (aOR: 4.26, 95% CI: 2.29–
7.94) (Table 2). The findings of the sensitivity analyses excluding
the ‘‘don’t know” responses for the study outcomes were generally
consistent with the results for the unrestricted analytical sample
(Supplemental Table 2). In addition to positive associations
between ever being vaccinated and receiving an HCP recommenda-
tion, there was some evidence to support associations between
confidence in the importance of maternal vaccines and trust in
information provided by HCPs and future vaccination intentions
in the sensitivity analysis (Supplemental Table 2).
3.3. Accepting vaccines while taking on a new nurturing role: A change
in perception
Women expressed more positive perceptions of vaccines in
general than maternal vaccines. Compared to vaccines in preg-
nancy, women were specifically more likely to agree (strongly
agree or tend to agree) that vaccines in general are important
(78% vs 35%), effective (72% vs 34%) and safe (28% vs 18%) (Fig. 1-
A-C). These differences were confirmed in the qualitative inter-
views, with women expressing strong fears around maternal
vaccination: ‘‘I get the impression that I’m scared more now because
I’m pregnant” (P11). Both women who support vaccination and
those with pre-existing doubts about vaccines used particularly
strong emotive language around the risks for their babies: ‘‘No.
No, I really don’t agree. Because during the pregnancy it is forbidden
to take any medicine (. . .). So, no, no immunisation. We have a baby
inside of us that is immunised against nothing so no. Not during preg-
nancy.” (P2) The difference in attitudes came together with a shift
in the role and responsibility that women must assume when they
become pregnant. In her new nurturing role, one woman described
maternal vaccination as a disruptor of peace: ‘‘I’m creating a baby, I
would rather create him peacefully and when he’s going to be out, I
will do all the vaccines peacefully” (P9).
3.4. Mistrust stemming from concerns about missing information
Just under a third of women surveyed (n = 157, 31%) reported
being aware of vaccines currently administered during pregnancy
(Table 1). Pregnant women questioned the need for maternal vac-
cination in the qualitative interviews and raised concerns about
not having received information or recommendations from official
sources, such as their HCPs or social security: ‘‘Unfortunately we are
not informed enough about vaccines and I think that’s why a lot of
people don’t get vaccinated, or don’t dare to do it” (T1). This seemed
to trigger worry and discontent with the general lack of health
information provided during pregnancy in France: ‘‘As a pregnant
woman, I do not believe we are sensitized enough about all the things
we could do during pregnancy” (P6).
In the survey, the most frequently reported sources of informa-
tion for vaccination decisions during pregnancy were HCPs (75%),
family members (29%) and the internet (26%) (Fig. 2). While HCPs
(74%) and family members (24%) were also listed as the most
trusted sources of information, the proportion of women who
trusted the internet for vaccination-related information was lower
(12%) (Fig. 2). During the interviews, women seemed to justify
their use of the internet, indicating a general acceptance that infor-
mation online is not trustworthy. Mistrust of information was also
raised more generally, with women repetitively asking for ‘‘proof”:
proof that vaccines are well tested, safe, effective and important.
Some discussed the trustworthiness of information provided in
the media as well as the possible influence of the pharmaceutical
industry: ‘‘How do you know that you’re getting the right informa-
Table 1
Characteristics of study participants and their associations with previous vaccination and future vaccination intention among pregnant and recently pregnant women in France:
2019.
Characteristics Categories Total, N
(%)
Ever vaccinated
during pregnancy
Intend to be
vaccinated in a
future pregnancy
n (%) P-
value
n (%) P-
value
Concerned about illness during pregnancy No or Don’t know 157 (31.4) 27 (17.2) 0.051 32 (20.4) 0.093
Yes 343 (68.6) 86 (25.1) 94 (27.4)
Aware of vaccines currently available for pregnant women No or Don’t know 343 (68.6) 36 (10.5) <0.001 56 (16.3) <0.001
Yes 157 (31.4) 77 (49.1) 70 (44.6)
Vaccines during pregnancy are important Not agree 325 (65.0) 34 (10.5) <0.001 39 (12.0) <0.001
Agree 175 (35.0) 79 (45.1) 87 (49.7)
Vaccines during pregnancy are safe Not agree 409 (81.8) 68 (16.6) <0.001 76 (18.6) <0.001
Agree 91 (18.2) 45 (49.4) 50 (54.9)
Vaccines during pregnancy are effective Not agree 332 (66.4) 36 (10.8) <0.001 39 (11.8) <0.001
Agree 168 (33.6) 77 (45.8) 87 (51.8)
Vaccines during pregnancy are compatible with my religious
beliefs
Not agree 266 (53.2) 44 (16.5) 0.001 46 (17.3) <0.001
Agree 234 (46.8) 69 (29.5) 80 (34.2)
Trust in information provided by health care workers No 129 (25.8) 27 (20.9) 0.599 23 (17.8) 0.025
Yes 371 (74.2) 86 (23.2) 10.3
(27.8)
Health care worker recommended a vaccine during pregnancy No or Don’t know 331 (66.2) 19 (5.7) <0.001 37 (11.2) <0.001
Yes 169 (33.8) 94 (55.6) 89 (52.7)
Decide on vaccination for self No 145 (29.0) 19 (5.7) <0.001 37 (11.2) <0.001
Yes 355 (71.0) 94 (55.6) 89 (52.7)
Pregnancy status Previously pregnant 386 (77.2) 75 (19.4) 0.002 91 (23.6) 0.124
Currently pregnant 114 (22.8) 38 (33.3) 35 (30.7)
Respondent age 18–24 years 40 (8.0) 11 (27.5) 0.093 7 (17.5) 0.205
25–34 years 305 (61.0) 59 (19.3) 73 (23.9)
35 + years 155 (31.0) 43 (27.7) 46 (29.7)
Marital status (n = 496) Not living with a partner or single 24 (4.8) 3 (12.5) 0.163* 6 (25.0) 0.981
Married or living with a partner 472 (95.2) 110
(23.2)
119
(25.2)
Annual household income (n = 484) Up to 20,000 € 121 (25.0) 24 (19.8) 0.026 33 (27.3) <0.001
20,000–39,999 € 196 (40.5) 40 (20.4) 38 (19.4)
40,000–59,999 € 103 (21.3) 22 (21.4) 23 (22.3)
60,000 € and above 64 (13.2) 24 (37.5) 29 (45.3)
Education (n = 493) Primary or others 24 (4.9) 7 (29.2) 0.010 5 (20.8) 0.318
Secondary 162 (32.9) 23 (14.2) 34 (21.0)
University or higher 307 (62.3) 80 (26.1) 83 (27.1)
Employment (n = 494) Not working 41 (8.3) 9 (21.9) 0.694 7 (17.1) 0.337
On maternity leave 149 (30.2) 30 (20.1) 35 (23.5)
Working (full or part-time) 304 (61.5) 72 (23.7) 82 (27.0)
Religion Atheist or Agnostic 146 (29.2) 33 (22.6) 0.925 37 (25.3) 0.956
Christian (Roman Catholic) 174 (34.8) 41 (23.6) 44 (25.3)
Christian (Protestant/Others) 26 (5.2) 7 (26.9) 8 (30.8)
Other religions (Muslim/Hindu/Buddhist
etc.)
83 (16.6) 16 (19.3) 19 (22.9)
Prefer not to say 71 (14.2) 16 (22.5) 18 (25.4)
*Uncorrected p-value from Fisher’s exact test.
 Uncorrected p-values from chi-square test.
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all it” (P11).
3.5. My body, my choice: decision-making during pregnancy
The majority of women surveyed (n = 355, 71%) reported mak-
ing decisions for vaccination during pregnancy by themselves, with
women in the qualitative interviews reporting the importance of
remaining in control of their pregnancy. While some mentioned
the role of their partner, it was often limited. Overall, women
expressed high confidence in listening to their own bodies, and
not being easily influenced by others: ‘‘When I ask a question, I
already have the answer, I already know what I must do, but [asking
others] validates my opinion” (P2). This confidence in one’s own
decision was particularly strong among women who refused vacci-
nation, while vaccinated pregnant women were more divided:
some remained uncertain about their decision, concerned about
the vaccine’s safety or effectiveness and others described accepting
the vaccine straight away, without any doubt.41203.6. HCPs and pregnant women: A relationship of trust
Women in interviews expressed strong trust in their HCPs, par-
ticularly during their pregnancy. Many women talked about the
fear of being treated like a number in a factory, and the importance
of HCPs taking a reassuring role, with a focus on personalised and
attentive care. For some, this meant placing their trust in mid-
wives, while others placed their trust in the perceived expertise
of gynaecologists. Having a trusting relationship with HCPs was
seen as a crucial component of a stress-free pregnancy: ‘‘I have
no medical notions, so I trust them (. . .). Maybe that’s why I don’t have
those fears that other mothers can have, because I have all those doc-
tors and I trust them.” (T5). While only a couple of women
expressed mistrust of HCPs, many expressed discontent about
HCPs not taking the time to discuss vaccination: ‘‘I have not yet
met a specialist, doctor, health professional that would be ready or
willing to speak about it in detail with me” (P8).
This strong and trusting relationship led some women to reject
maternal vaccination as a result of their HCP not recommending
Table 2
Characteristics associated with maternal vaccination uptake and future vaccination intentions among pregnant and recently pregnant women in France: 2019.
Characteristics Categories Total, N
(%)
Ever vaccinated during pregnancy
(N = 477)
Intend to be vaccinated in a future
pregnancy (N = 484)
Crude OR (95% CI)

Adjusted OR (95%
CI)y
Crude OR (95%
CI) 
Adjusted OR (95%
CI) y
Aware of vaccines currently available for pregnant
women
No or Don’t
know
343
(68.6)
Ref Ref – –
Yes 157
(31.4)
8.21 (5.15–13.08)
***
3.65 (2.06–6.44)
***
– –
Vaccines during pregnancy are effective Not agree 332
(66.4)
Ref Ref Ref Ref
Agree 168
(33.6)
6.96 (4.39–11.02)
***
3.44 (1.96–6.05)
***
8.07 (5.14–
12.67)***
3.83 (2.25–6.50)
***
Trust in information provided by health care
workers
No 129
(25.8)
– – Ref Ref
Yes 371
(74.2)
– – 1.77 (1.07–2.94)* 2.03 (1.07–3.83)
Health care worker recommended a vaccine
during pregnancy
No or Don’t
know
331
(66.2)
Ref Ref Ref Ref
Yes 169
(33.8)
20.58 (11.83–
35.80)***
11.10 (6.06–
20.34)***
8.84 (5.60–
13.95)***
3.27 (1.80–5.93)**
Ever vaccinated during pregnancy No or Don’t
know
387
(77.4)
– – Ref Ref
Yes 113
(22.6)
– – 12.22 (7.52–
19.86)***
4.26 (2.29–7.93)
***
Annual household income Up to 20,000 € 121
(25.0)
– – Ref Ref
20,000–39,999
€
196
(40.5)
– – 0.64 (0.38–1.09) 0.53 (0.27–1.01)
40,000–59,999
€
103
(21.3)
– – 0.76 (0.42–1.41) 0.49 (0.23–1.04)
60,000 € and
above
64 (13.2) – – 2.21 (1.17–4.17)* 1.17 (0.53–2.60)
 Uncorrected p-values: * Significant at p < 0.05 , ** Significant at p < 0.01, ***Significant at p < 0.001.
y olm-Bonferroni corrected p-values: * Significant at p < 0.05 , ** Significant at p < 0.01, ***Significant at p < 0.001.
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pharmacy to pick up the vaccine and to get vaccinated on the same
day by the doctor. (. . .) [But] I wanted to follow his opinion, so I didn’t
do it.” (T5). Only just over a third of women surveyed (n = 169, 34%)
reported receiving an HCP recommendation for vaccination during
their pregnancy (Table 1). Reports of doctors questioning the need,
reliability or risk of maternal vaccination were influential on
women’s decisions in interviews.
Even in a context of high trust, doctors’ recommendations were
not always sufficient to convince women to receive a maternal vac-
cine, pointing to the influence of other factors in decision-making.
The approach taken by HCPs also played a role, with women trust-
ing their doctors more if they advised rather than pressured them
to vaccinate.
3.7. Why vaccinate if you still have a risk of being sick?
Interviewed pregnant women who had refused influenza vacci-
nation raised questions about the need for the vaccine, together
with the perception that they would still be at risk of catching
influenza after vaccination. Some referred to their personal experi-
ences of catching the flu after getting vaccinated, while others
relied on testimonies from the internet: ‘‘I heard a lot of things
around me and on the internet about people who have been vacci-
nated and who still had the flu. (. . .) Why do it if it’s to have the flu
after it” (T1).
3.8. The importance of avoiding illnesses during pregnancy
Susceptibility to influenza was discussed as an influential factor
for accepting as well as refusing vaccination during pregnancy.
Vaccinated women showed a perceived high risk of catching the
flu linked to past infection, working in a high-risk environment,4121or the belief that pregnancy makes women more at risk of catching
the flu. On the other hand, some women refused the flu vaccine
because they did not feel at particular risk (e.g., not pregnant dur-
ing winter, not an ‘‘at-risk” person, not exposed to flu).
Over two-thirds of the women surveyed (n = 343, 69%) indi-
cated that they were concerned about illnesses during pregnancy
(Table 1). While flu was rarely described as a severe disease in
the qualitative interviews, women discussed the importance of
preventing any type of illness during their pregnancy, even the
more benign ones: ‘‘There have been many cases of flu (. . .) and I
see in my Facebook group that the mums are all very worried about
catching it.” (P6). While some women worried about their personal
risk of complications from infections during their pregnancy (i.e.,
because they would not be able to take medicines, or care for their
other children if sick), most referred to risks for their babies, such
as miscarriages. Many women agreed they would vaccinate them-
selves against extremely dangerous diseases to protect their
babies. The importance of vaccination to protect communities
and those around them was also raised.
3.9. Emotional reactions to invisible risks
Concerns about safety were raised by women during interviews
regardless of their vaccination status, with mentions of ‘‘risk” and
‘‘danger” for their babies. Specific side effects, apart from malfor-
mation and miscarriages, were not commonly discussed. Women
instead expressed strong uncertainty surrounding the safety of
vaccines: ‘‘R: I don’t want to inject a product like this to a human
being who lives inside me. I: What are you afraid of? R: The unknown,
we do not know what the final result is and we will never know!” (P1).
The thought that women cannot see what happens to their baby
created the feeling of an ‘‘invisible” risk, which made them even
more anxious: ‘‘if something goes wrong in my womb it’s going to
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Fig. 1. A–C: Women’s perceptions toward the importance, safety, and effectiveness of vaccines in general and during pregnancy in the survey (N = 500).
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Fig. 2. Women’s sources of information and trust in these sources when making decisions on vaccination during pregnancy. Data from the survey (N = 500). Multiple
responses were allowed.
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doubts about vaccine safety as unlikely to change. They did not
question vaccine safety, but how long it would take for risks to
be exposed. In fact, few women showed high confidence in vaccine
safety, with those who did expressing trust in science or HCPs: ‘‘if it
was risky, they would not propose it” (T11).
Vaccine safety was an emotional topic for pregnant women.
Women reacted strongly to the thought of receiving a vaccine dur-
ing pregnancy, using emotive language (‘‘brutal”, ‘‘enormous”), rep-
etitions and exclamations: ‘‘No way he’s touching me!” (P12). Some
women also discussed their responsibility and guilt if something
bad were to happen: ‘‘You don’t know how to proceed afterwards.
What do you do if it goes wrong for the baby?” (P2). Emotional
responses were reinforced when the discussion concerned their
babies (‘‘I’m afraid for the health of the baby, not for myself (. . .) I
don’t care about myself,” (T7)), with some discussing a maternal
instinct that would be difficult to change.
Being pregnant also changed some women’s tolerance for risks:
the notion that you should avoid taking any risk during pregnancy,
from smoking to drinking alcohol was very important: ‘‘You have to
avoid taking certain medications, even if they say you can. You have to
be careful” (P11). Medications were also perceived as risky, which
made some women question maternal vaccination: ‘‘They tell us
that small medicines are forbidden, even cough syrup is forbidden,
so I don’t really understand why this would be authorised” (P2).4. Discussion
This study has found that vaccine uptake among pregnant
women is low in France, with just over a fifth (23%) of women
reporting ever being vaccinated during pregnancy and a similar
proportion (25%) intending to be vaccinated in future pregnancies.
While this compares to previous studies [6,14,15], understanding
the reasons behind this low uptake is key to informing strategies
to support maternal vaccination. Our study found that having a
general awareness of maternal vaccines, being confident about
the effectiveness of vaccines during pregnancy and receiving an
HCP recommendation for vaccination were positively associated
with maternal vaccination uptake. The strongest predictor of
women’s future vaccination intentions was having received a vac-
cination during a previous pregnancy. These findings are compara-
ble to previous studies conducted in France and across the world
[6,8,10,16–19].
By combining quantitative and qualitative data, our study was
able to provide more in-depth understanding of the scope and
scale of pregnant women’s beliefs, emotions and decision-
making. While no strong association was identified between vac-
cine safety and maternal vaccination uptake in the quantitative
analysis, in-depth conversations revealed a more generalised con-
sensus that vaccines may be unsafe, consistent with existing evi-
dence [6,8,10]. When making decisions about vaccination,
pregnant women did not question whether vaccines are safe, but
whether - and when - the real risks would be exposed. This mirrors
confidence issues observed in the general population, with global
studies showing that a high proportion of adults in France question
the safety of vaccines [9,20,21]. Women’s tolerance for risk was
also shown to decrease during pregnancy, especially when consid-
ering ‘‘invisible risks” related to the uncertainty of not seeing what
might happen to their babies during pregnancy. This could in part
be due to an ‘‘omission bias” and individuals’ preference for risks
related to non-vaccination over risks related to the active act of
vaccination [22].
Pregnant women in this study were much less likely to perceive
maternal vaccines as important, effective and safe than childhood
vaccines; and when compared to the 2018 EU Vaccine Confidence4123survey, were also found to be less confident than the French gen-
eral population (Supplementary Fig. 1) [20]. This could be
explained by pregnancy being a relatively complex and emotional
period for women to reason about risks, as their responsibility
shifts from making decisions and assessing risks for themselves
to thinking about both their own and their baby’s health [24].
These emotional changes could impact vaccination intentions, sup-
porting the concept of ‘‘emotional determinants of health” [25].
Our study showed that women often used very emotional language
when talking about maternal vaccination, particularly risks. Chap-
man and colleagues have shown that emotions can mediate risk
perceptions, with worry about the risk and severity of diseases
prompting preventive action [23]. This protective emotional reac-
tion was observed in this study, with women taking on a nurturing
role and discussing the importance of protecting their children
against any type of diseases.
Both the qualitative and quantitative findings from our study
revealed a paradox in maternal vaccination decision-making:
while pregnant women expressed the conviction that maternal
vaccination should remain a personal decision, the influence of
HCPs on their decision was evident. The ‘‘my body, my choice” nar-
rative has been central to discussions around women and repro-
ductive health, including vaccination [26,27]. In this study,
pregnant women reflected on the importance of being in control
of their pregnancies and listening to their own voice. This points
to the need for communication campaigns to shift their focus from
imposing maternal vaccination to engaging with and empowering
pregnant women. Shared-decision making can help reduce anxiety,
lower decision conflict and increase knowledge and satisfaction
[28,29].
Healthcare professionals can play a key role in facilitating dia-
logue, as part of a trustworthy yet informed relationship. This
study has shown the powerful impact HCPs can have when they
offer a reassuring, compassionate and attentive presence. Unfortu-
nately, studies have shown that HCPs themselves might be losing
confidence in vaccination in France [30,31], which has been
reflected in this study with some women reporting that HCPs were
not recommending or recommending against maternal vaccina-
tion. The influence of hesitant HCPs, particularly midwives and
gynaecologists who might be less commonly involved in vaccina-
tion communications, comes at a crucial time when women are
forming their opinions about vaccination as pregnant women,
and as future mothers.
The major strength of this study has been the use of a mixed
method approach to provide a comprehensive picture of pregnant
women’s beliefs, perceptions, emotions, and confidence in mater-
nal vaccination in France. Some limitations should be highlighted.
Participants in the quantitative survey were recruited using quota
sampling, a type of non-probability sampling, to form a study sam-
ple that were approximately representative of the regional popula-
tion distribution in France. Non-probability sampling may not offer
the same level of population representativeness as probability-
based sampling. It is important to note that less than a quarter of
the women (n = 114, 23%) were pregnant during the survey, sug-
gesting that the potential for recall bias around previous maternal
vaccinations may be high. While we were unable to verify these
self-reported data by reviewing medical records, we assessed
women’s intention to be vaccinated in future pregnancies as a sup-
plemental indictor of maternal vaccination acceptance in our
study. Weighting of study proportions and regression estimates
was not possible due to lack of national data on the distribution
of currently and previously pregnant women. We used a parsimo-
nious modelling approach employing stepwise regression, which
can sometimes yield biased regression coefficients in addition to
the increased probability of Type I errors [13]. We compared the
stepwise models with the full models (with no variable selection
E. Karafillakis, M.R. Francis, P. Paterson et al. Vaccine 39 (2021) 4117–4125performed) for each of the study outcomes using Likelihood Ratio
Tests (LRTs), there was no evidence to suggest an improved fit
for the full models (Supplemental Table 3). It is also important to
consider the cross-sectional nature of the surveys, which limits
causal inference from the observed associations. Furthermore,
while the impact of the interviewer on participant responses in
the qualitative study is non-negligible, bias was limited by using
a trained French speaking female researcher and reliability was
guaranteed by using good fieldwork and analysis practices as well
as comprehensive analysis of the entire data set. French interviews
were translated and transcribed into English, which could have
contributed to some concepts being lost in translation. This was
mitigated by close listening to the audio-recordings by the
French-speaking researcher analysing the data.
Many of the factors explaining low maternal vaccination uptake
in France are similar to those found in other parts of the world, but
they are complex and need to be understood as part of a period of
change for pregnant women. While the importance of HCPs in
pregnant women’s decisions is not unique to France, the strong
relationship based on trust could be detrimental if HCPs in France
are losing confidence in vaccination. The patient-doctor relation-
ship also needs to be explored further, especially looking at
changes throughout women’s lives, from adolescence to pregnancy
and parenthood, as opinions, values and trust evolve with time.
Women’s low awareness about maternal vaccination represents a
missed opportunity to shape positive attitudes towards vaccina-
tion in the mothers of tomorrow. We highlight the importance of
the role of emotions in decision-making around vaccines during
pregnancy. More studies should be conducted to explore the evo-
lution of beliefs and emotions from pregnancy to motherhood. Per-
ceptions of risk are complex and HCPs need to take the time to
listen to concerns rather than dismiss them. This will be crucial
in the context of new vaccines being developed for pregnancy,
especially with the threat of pandemics from the emergence of
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